Pall Corp.

As with any therapeutic, the design of the manufacturing process is central in being able to efficiently produce, and provide patients with, quality treatments. For cell and gene therapies (CGTs), how

Device Transactions Device companies aggregated $2.4 billion in financing for the fourth quarter of 2016, representing an 18% decrease from Q3's $3 billion. Despite the decline, Q4 put up the second-s

Device Transactions Device companies raised a total of $1.2 billion in financing in the fourth quarter, a 16% decrease from Q3's $1.4 billion. Q4 turned out to have the second-lowest financing aggrega

Medtech M&A activity has been on the rise for several years and shows no signs of slowing down. The industry has seen its deals getting bigger and bigger, giving way to a surge in the number of higher